Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE.

Zandee WT, Feelders RA, Smit Duijzentkunst D, Hofland J, Metselaar RM, Oldenburg RA, van Linge A, Kam BLR, Teunissen J, Korpershoek E, Hendriks J, Abusaris H, Slagter C, Franssen GJH, Brabander T, de Herder W.

Eur J Endocrinol. 2019 May 1. pii: EJE-18-0901.R1. doi: 10.1530/EJE-18-0901. [Epub ahead of print]

PMID:
31067510
2.

Acceleration of Inverse Molecular Design by Using Predictive Techniques.

Teunissen JL, De Proft F, De Vleeschouwer F.

J Chem Inf Model. 2019 Jun 24;59(6):2587-2599. doi: 10.1021/acs.jcim.8b00654. Epub 2019 May 15.

PMID:
31063374
3.

Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors.

Zandee WT, Brabander T, Blažević A, Kam BLR, Teunissen JJM, Feelders RA, Hofland J, de Herder WW.

J Clin Endocrinol Metab. 2019 Apr 1;104(4):1336-1344. doi: 10.1210/jc.2018-01991.

PMID:
30566620
4.

Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours.

van der Zwan WA, Brabander T, Kam BLR, Teunissen JJM, Feelders RA, Hofland J, Krenning EP, de Herder WW.

Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):704-717. doi: 10.1007/s00259-018-4158-1. Epub 2018 Sep 28.

5.

Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial).

Braat AJAT, Kwekkeboom DJ, Kam BLR, Teunissen JJM, de Herder WW, Dreijerink KMA, van Rooij R, Krijger GC, de Jong HWAM, van den Bosch MAAJ, Lam MGEH.

BMC Gastroenterol. 2018 Jun 15;18(1):84. doi: 10.1186/s12876-018-0817-8.

6.

Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour.

da Silva TN, van Velthuysen MLF, van Eijck CHJ, Teunissen JJ, Hofland J, de Herder WW.

Endocrinol Diabetes Metab Case Rep. 2018 Apr 11;2018. pii: 18-0015. doi: 10.1530/EDM-18-0015. eCollection 2018.

7.

Tumor classification with MALDI-MSI data of tissue microarrays: A case study.

Mascini NE, Teunissen J, Noorlag R, Willems SM, Heeren RMA.

Methods. 2018 Dec 1;151:21-27. doi: 10.1016/j.ymeth.2018.04.004. Epub 2018 Apr 12.

8.

Lack of 14-3-3 proteins in Saccharomyces cerevisiae results in cell-to-cell heterogeneity in the expression of Pho4-regulated genes SPL2 and PHO84.

Teunissen JHM, Crooijmans ME, Teunisse PPP, van Heusden GPH.

BMC Genomics. 2017 Sep 6;18(1):701. doi: 10.1186/s12864-017-4105-8.

9.

Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors.

Bergsma H, van Lom K, Raaijmakers MHGP, Konijnenberg M, Kam BLBLR, Teunissen JJM, de Herder WW, Krenning EP, Kwekkeboom DJ.

J Nucl Med. 2018 Mar;59(3):452-458. doi: 10.2967/jnumed.117.189712. Epub 2017 Aug 3.

10.

Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors.

Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, van Eijck CHJ, Franssen GJH, Krenning EP, Kwekkeboom DJ.

Clin Cancer Res. 2017 Aug 15;23(16):4617-4624. doi: 10.1158/1078-0432.CCR-16-2743. Epub 2017 Apr 20.

11.

Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate.

Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, de Herder WW, Feelders RA, Krenning EP, Kwekkeboom DJ.

Endocr Relat Cancer. 2017 May;24(5):243-251. doi: 10.1530/ERC-16-0524. Epub 2017 Mar 20.

PMID:
28320783
12.

Tuning the HOMO-LUMO Energy Gap of Small Diamondoids Using Inverse Molecular Design.

Teunissen JL, De Proft F, De Vleeschouwer F.

J Chem Theory Comput. 2017 Mar 14;13(3):1351-1365. doi: 10.1021/acs.jctc.6b01074. Epub 2017 Feb 28.

PMID:
28218844
13.
14.

Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate.

Bergsma H, Konijnenberg MW, van der Zwan WA, Kam BL, Teunissen JJ, Kooij PP, Mauff KA, Krenning EP, Kwekkeboom DJ.

Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1802-11. doi: 10.1007/s00259-016-3382-9. Epub 2016 May 10.

15.

Peptide receptor radionuclide therapy of neuroendocrine tumours.

Brabander T, Teunissen JJ, Van Eijck CH, Franssen GJ, Feelders RA, de Herder WW, Kwekkeboom DJ.

Best Pract Res Clin Endocrinol Metab. 2016 Jan;30(1):103-14. doi: 10.1016/j.beem.2015.10.005. Epub 2015 Oct 8. Review.

PMID:
26971847
16.

Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course.

Bergsma H, Konijnenberg MW, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, Franssen GJ, van Eijck CH, Krenning EP, Kwekkeboom DJ.

Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):453-63. doi: 10.1007/s00259-015-3193-4. Epub 2015 Sep 30.

17.

Nuclear Medicine Imaging of Neuroendocrine Tumors.

Brabander T, Kwekkeboom DJ, Feelders RA, Brouwers AH, Teunissen JJ.

Front Horm Res. 2015;44:73-87. doi: 10.1159/000382059. Epub 2015 Aug 14. Review.

PMID:
26303705
18.

Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate.

van Vliet EI, van Eijck CH, de Krijger RR, Nieveen van Dijkum EJ, Teunissen JJ, Kam BL, de Herder WW, Feelders RA, Bonsing BA, Brabander T, Krenning EP, Kwekkeboom DJ.

J Nucl Med. 2015 Nov;56(11):1647-53. doi: 10.2967/jnumed.115.158899. Epub 2015 Aug 13.

19.

The effect of 3% and 6% hypertonic saline in viral bronchiolitis: a randomised controlled trial.

Teunissen J, Hochs AH, Vaessen-Verberne A, Boehmer AL, Smeets CC, Brackel H, van Gent R, Wesseling J, Logtens-Stevens D, de Moor R, Rosias PP, Potgieter S, Faber MR, Hendriks HJ, Janssen-Heijnen ML, Loza BF.

Eur Respir J. 2014 Oct;44(4):913-21. doi: 10.1183/09031936.00159613. Epub 2014 Jun 25.

20.

Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments.

Bison SM, Konijnenberg MW, Melis M, Pool SE, Bernsen MR, Teunissen JJ, Kwekkeboom DJ, de Jong M.

Clin Transl Imaging. 2014;2:55-66. Epub 2014 Mar 5. Review.

21.

Prenatal detection of an enteric duplication cyst.

Teunissen J, Dams A, Bruneel E.

Acta Chir Belg. 2013 Sep-Oct;113(5):355-6.

PMID:
24294801
22.

Comparison of response evaluation in patients with gastroenteropancreatic and thoracic neuroendocrine tumors after treatment with [177Lu-DOTA0,Tyr3]octreotate.

van Vliet EI, Krenning EP, Teunissen JJ, Bergsma H, Kam BL, Kwekkeboom DJ.

J Nucl Med. 2013 Oct;54(10):1689-96. doi: 10.2967/jnumed.112.117408.

23.

Particle on a boron disk: ring currents and disk aromaticity in B20(2-).

Tai TB, Havenith RW, Teunissen JL, Dok AR, Hallaert SD, Nguyen MT, Ceulemans A.

Inorg Chem. 2013 Sep 16;52(18):10595-600. doi: 10.1021/ic401596s. Epub 2013 Sep 6.

PMID:
24011355
24.

Hypocalcaemia after treatment with [177Lu-DOTA 0,Tyr3]octreotate.

van Vliet EI, de Herder WW, de Rijke YB, Zillikens MC, Kam BL, Teunissen JJ, Peeters RP, Krenning EP, Kwekkeboom DJ.

Eur J Nucl Med Mol Imaging. 2013 Dec;40(12):1843-52. doi: 10.1007/s00259-013-2503-y. Epub 2013 Jul 23.

PMID:
23877632
25.

Peptide receptor radionuclide therapy (PRRT) for GEP-NETs.

Bergsma H, van Vliet EI, Teunissen JJ, Kam BL, de Herder WW, Peeters RP, Krenning EP, Kwekkeboom DJ.

Best Pract Res Clin Gastroenterol. 2012 Dec;26(6):867-81. doi: 10.1016/j.bpg.2013.01.004.

PMID:
23582925
26.

Increased mammary uptake on 111In pentetreotide scintigraphy.

Van Eeckhoudt SF, Teunissen JJ, Kwekkeboom DJ.

Clin Nucl Med. 2012 Aug;37(8):781-2. doi: 10.1097/RLU.0b013e31824851f0.

PMID:
22785510
27.

Tumor response assessment to treatment with [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors: differential response of bone versus soft-tissue lesions.

van Vliet EI, Hermans JJ, de Ridder MA, Teunissen JJ, Kam BL, de Krijger RR, Krenning EP, Kwekkeboom DJ.

J Nucl Med. 2012 Sep;53(9):1359-66. doi: 10.2967/jnumed.112.102871. Epub 2012 Jul 10.

28.

Lutetium-labelled peptides for therapy of neuroendocrine tumours.

Kam BL, Teunissen JJ, Krenning EP, de Herder WW, Khan S, van Vliet EI, Kwekkeboom DJ.

Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1:S103-12. doi: 10.1007/s00259-011-2039-y. Review.

29.

Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy.

van Vliet EI, Teunissen JJ, Kam BL, de Jong M, Krenning EP, Kwekkeboom DJ.

Neuroendocrinology. 2013;97(1):74-85. doi: 10.1159/000335018. Epub 2012 Jan 10. Review.

PMID:
22237390
30.

Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.

Teunissen JJ, Kwekkeboom DJ, Valkema R, Krenning EP.

Endocr Relat Cancer. 2011 Oct 17;18 Suppl 1:S27-51. doi: 10.1530/ERC-10-0282. Print 2011 Oct. Review.

PMID:
22005114
31.

Improved control of severe hypoglycemia in patients with malignant insulinomas by peptide receptor radionuclide therapy.

van Schaik E, van Vliet EI, Feelders RA, Krenning EP, Khan S, Kamp K, Valkema R, van Nederveen FH, Teunissen JJ, Kwekkeboom DJ, de Herder WW.

J Clin Endocrinol Metab. 2011 Nov;96(11):3381-9. doi: 10.1210/jc.2011-1563. Epub 2011 Sep 14.

PMID:
21917872
32.

Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate.

Khan S, Krenning EP, van Essen M, Kam BL, Teunissen JJ, Kwekkeboom DJ.

J Nucl Med. 2011 Sep;52(9):1361-8. doi: 10.2967/jnumed.111.087932. Epub 2011 Jul 27.

33.

Preclinical and clinical studies of peptide receptor radionuclide therapy.

Pool SE, Krenning EP, Koning GA, van Eijck CH, Teunissen JJ, Kam B, Valkema R, Kwekkeboom DJ, de Jong M.

Semin Nucl Med. 2010 May;40(3):209-18. doi: 10.1053/j.semnuclmed.2009.12.001. Review.

PMID:
20350630
34.

Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.

Kwekkeboom DJ, de Herder WW, van Eijck CH, Kam BL, van Essen M, Teunissen JJ, Krenning EP.

Semin Nucl Med. 2010 Mar;40(2):78-88. doi: 10.1053/j.semnuclmed.2009.10.004. Review.

PMID:
20113677
35.

Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.

Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, de Jong M, de Herder WW, Krenning EP.

Endocr Relat Cancer. 2010 Jan 29;17(1):R53-73. doi: 10.1677/ERC-09-0078. Print 2010 Mar. Review.

PMID:
19995807
36.

Extensive soft-tissue metastases from malignant pleural mesothelioma.

Aukema TS, Teunissen JJ, Burgers SA, van Pel R, Vogel WV.

J Clin Oncol. 2009 Jul 20;27(21):e24-5. doi: 10.1200/JCO.2008.21.0351. Epub 2009 Jun 8. No abstract available.

PMID:
19506158
37.

Effects of therapy with [177Lu-DOTA 0,Tyr 3]octreotate on endocrine function.

Teunissen JJ, Krenning EP, de Jong FH, de Rijke YB, Feelders RA, van Aken MO, de Herder WW, Kwekkeboom DJ.

Eur J Nucl Med Mol Imaging. 2009 Nov;36(11):1758-66. doi: 10.1007/s00259-009-1151-8. Epub 2009 May 27.

38.

Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate.

Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH, Teunissen JJ, de Jong M, van Lom K, de Herder WW, Kwekkeboom DJ.

Eur J Nucl Med Mol Imaging. 2009 Jul;36(7):1138-46. doi: 10.1007/s00259-009-1072-6. Epub 2009 Feb 27.

39.

Multimodality management of a polyfunctional pancreatic endocrine carcinoma with markedly elevated serum vasoactive intestinal polypeptide and calcitonin levels.

Nasir A, Gardner NM, Strosberg J, Ahmad N, Choi J, Malafa MP, Coppola D, Kwekkeboom DJ, Teunissen JJ, Kvols LK.

Pancreas. 2008 Apr;36(3):309-13. doi: 10.1097/MPA.0b013e31815b321c.

PMID:
18362846
40.

Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues.

Kwekkeboom DJ, Teunissen JJ, Kam BL, Valkema R, de Herder WW, Krenning EP.

Hematol Oncol Clin North Am. 2007 Jun;21(3):561-73; x. Review.

PMID:
17548040
41.

Breath condenser coatings affect measurement of biomarkers in exhaled breath condensate.

Rosias PP, Robroeks CM, Niemarkt HJ, Kester AD, Vernooy JH, Suykerbuyk J, Teunissen J, Heynens J, Hendriks HJ, Jöbsis Q, Dompeling E.

Eur Respir J. 2006 Nov;28(5):1036-41. Epub 2006 Jul 26.

42.

Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?

Esser JP, Krenning EP, Teunissen JJ, Kooij PP, van Gameren AL, Bakker WH, Kwekkeboom DJ.

Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1346-51. Epub 2006 Jul 18.

PMID:
16847654
43.

Molecular radiotherapy with somatostatin analogs for (neuro-)endocrine tumors.

Krenning EP, Teunissen JJ, Valkema R, deHerder WW, deJong M, Kwekkeboom DJ.

J Endocrinol Invest. 2005;28(11 Suppl International):146-50. Review.

PMID:
16625865
44.

Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs.

Teunissen JJ, Kwekkeboom DJ, Krenning EP.

Trends Endocrinol Metab. 2006 Jan-Feb;17(1):19-25. Epub 2005 Nov 28. Review.

PMID:
16311041
45.

Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy.

Teunissen JJ, Kwekkeboom DJ, de Jong M, Esser JP, Valkema R, Krenning EP.

Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):595-616. Review.

PMID:
16183530
46.

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors.

Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, Esser JP, Kam BL, Krenning EP.

J Clin Oncol. 2005 Apr 20;23(12):2754-62.

PMID:
15837990
47.

Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma.

Teunissen JJ, Kwekkeboom DJ, Kooij PP, Bakker WH, Krenning EP.

J Nucl Med. 2005 Jan;46 Suppl 1:107S-14S.

48.

Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate.

Teunissen JJ, Kwekkeboom DJ, Krenning EP.

J Clin Oncol. 2004 Jul 1;22(13):2724-9.

PMID:
15226340
49.

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate.

Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, de Jong M, Srinivasan A, Erion JL, Krenning EP.

Eur J Nucl Med Mol Imaging. 2003 Mar;30(3):417-22. Epub 2003 Jan 9.

50.

Influence of litter size and breed on the duration of gestation in dogs.

Okkens AC, Teunissen JM, Van Osch W, Van Den Brom WE, Dieleman SJ, Kooistra HS.

J Reprod Fertil Suppl. 2001;57:193-7.

PMID:
11787149

Supplemental Content

Loading ...
Support Center